Get all premium features to the best stock analysis tool

Nxera Pharma to Receive US$3 Million Milestone Payment from Centessa Pharmaceuticals

Tokyo, Japan and Cambridge, UK, 5 March 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that Centessa Pharmaceuticals has achieved an additional early development milestone associated with its investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist, ORX489, being developed by Centessa for the treatment of neuropsychiatric disorders. This milestone triggers a payment of US$3 million to Nxera pursuant to its research collaboration with Centessa. The milestone payment will be recognized as revenue in the first quarter of 2026.

Nxera Pharma to Receive $1.8 Million Milestone Payment from Centessa Pharmaceuticals

Tokyo, Japan and Cambridge, UK, 12 February 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today notes that Centessa Pharmaceuticals has achieved an early development milestone associated with its investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist, ORX489, being developed by Centessa for the treatment of neuropsychiatric disorders. This milestone triggers a payment of US$1.8 million to Nxera pursuant to its research collaboration with Centessa. The milestone payment will be recognized as revenue in the first quarter of 2026.

Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting

Antidepressive effects and enhanced wakefulness were observed with OX2R activation in established animal model of major depressive disorder Antidepressive effects and enhanced wakefulness were observed with OX2R activation in established animal model of major depressive disorder

Nxera Pharma to Receive US$3.6 Million in Milestone Payment Pursuant to Research Collaboration with Centessa

Tokyo, Japan and Cambridge, UK, 13 January 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) notes that Centessa Pharmaceuticals has achieved an early development milestone associated with its investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist, ORX142, in development for the treatment of neurological and neurodegenerative disorders. This milestone triggers a payment of US$3.6 million to Nxera pursuant to its research collaboration with Centessa. The milestone payment will be recognised as revenue in Q4 FY2025.